WebPhase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer … WebThe results support tarlatamab as the first half-life–extended BiTE ® immune-oncology therapy in SCLC with an acceptable safety profile and encouraging efficacy across the dose range (i.e., 0.003-100 mg i. v. 2-weekly). Confirmed partial responses were observed in 20 % of patients, and the disease control rate was 47 %.
History of Changes for Study: NCT03319940 - clinicaltrials.gov
WebJan 7, 2024 · Prior palliative radiotherapy must have been completed at least 7 days before the first dose of Tarlatamab Participants who received androgen signaling inhibitor are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to … WebTarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). ... Tarlatamab (IP; 12 μg/kg; single dose) has a mean half-life of 234 hours (9.8 days), a mean clearance of … leiaut online
Tarlatamab on Relapsed/Refractory Small Cell Lung Cancer
WebApr 14, 2024 · Beyond AACR23: Immunotherapy that targets DLL3 in SCLC. In SCLC, Amgen is building on a deep legacy in a class of immunotherapies known as T-cell engagers to advance a first-in-class half-life extended (HLE) bispecific T-cell engager (BiTE ®) molecule, tarlatamab, that targets the delta-like ligand 3 protein, also known as DLL3. WebSep 1, 2024 · Tarlatamab (AMG 757), a half-life extended bispecific T cell engager (HLE BiTE®) molecule, binds DLL3 and CD3 leading to T cell-mediated tumor lysis. Interim … WebAug 8, 2024 · Tarlatamab delivered a confirmed ORR of 23% (confirmed and unconfirmed responses), a median duration of response of 13.0 months and a median overall survival (OS) of 13.2 months.... leichtketten sammelurin